Victoria Socha
Articles by Victoria Socha
A review and meta-analysis revealed an association between crescents and worsened renal outcomes in patients with IgAN.
IgAN treated with long-term corticosteroids may lead to adverse outcomes and increased clinical burden.
Elevated glucose uptake in adipose tissue of patients with gout may contribute to CKD progression.
Tirzepatide linked to reduced muscle fat infiltration and volume in type 2 diabetes, per SURPASS-3 MRI substudy findings.
Chronic hyperglycemia in pediatric type 1 diabetes may impair white matter development; brain changes persist into puberty.
Nearly half of U.S. patients discontinued semaglutide within 5 months, with cost a key barrier to continued use.
Cryo-electron microscopy shed light on the molecular structure of urate transporter 1 and mechanisms behind four gout drugs.
Gene sequencing of a patient with gouty sacroiliitis and gouty nephropathy highlighted genetic factors leading to gout.
Infliximab therapy for Crohn’s disease is linked to a high risk for IgAN, a study found.
Moderate-to-severe chronic arteriolar lesions were found to be independent risk factors for adverse renal prognosis in IgAN.
Pain coping skills training demonstrated benefits for patients on maintenance hemodialysis in a randomized clinical trial.
Hemodialysis patients reporting shorter sleep or problems sleeping had a higher mortality risk in an observational study.
Finerenone had kidney and cardiovascular benefits for patients with CKD even after an acute eGFR change occurred.
Higher cardiovascular mortality risk was associated with higher CKM syndrome stage, research showed.
A dual SGLT inhibitor may have ischemic benefits for patients with CKD, T2D, and cardiovascular risks, a study found.
An analysis of CKD trials supported 3-year total slope as the primary slope-based outcome in randomized trials.
Cyclophosphamide-rituximab therapy and minimal use of glucocorticoids in ANCA-associated vasculitis may reduce morbidity.
The race of patients with ADPKD affects waitlist experience, allograft quality, and post-transplant outcomes, a study found.
A study of real-world data found that tolvaptan reduced long-term kidney function decline in ADPKD.
Using serum cystatin C as a biomarker for AKI could prove to be a valuable addition to diagnostic protocols, a study reports.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.